SHS_610036 KOWK CGIL 16072

A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects With Chronic Hepatitis C Infection

This Registry is designed to provide long term clinical and virologic follow up in participants who have achieved sustained virologic response (SVR) while participating in a previous Gilead sponsored hepatitis C virus (HCV) study. This long term follow up study is observational and no treatment is provided for HCV.

Inclusion Criteria:

Have previously participated in a Gilead-sponsored hepatitis C study and received at least one Gilead oral antiviral agent (OAV)
Have achieved SVR in a Gilead-sponsored study, as defined in the original treatment protocol
Provide written, informed consent
Be willing and able to comply with the visit schedule and protocol-mandated procedures

Exclusion Criteria:

Individuals planning to start a new course of hepatitis C therapy including any investigational drug or device during the course of the follow-up Registry
History of clinically significant illness or any other major medical disorder that may interfere with follow up, assessments, or compliance with the protocol
N/A
NCT01457755
All Other
Hepatic
Kris Kowdley, M.D.
Gilead Sciences, Inc.
  • Swedish Medical Center